Get the Stockscreener App
4.52
0.44%
-0.02
After Hours:
4.50
-0.02
-0.44%
Niagen Bioscience Inc stock is traded at $4.52, with a volume of 628.84K.
It is down -0.44% in the last 24 hours and down -15.20% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$4.54
Open:
$4.58
24h Volume:
628.84K
Relative Volume:
0.54
Market Cap:
$361.96M
Revenue:
$129.42M
Net Income/Loss:
$17.38M
P/E Ratio:
22.12
EPS:
0.2043
Net Cash Flow:
$13.15M
1W Performance:
-0.66%
1M Performance:
-15.20%
6M Performance:
-51.97%
1Y Performance:
-39.89%
1-Day Range:
$4.5001
$4.65
1-Week Range:
$4.5001
$4.95
52-Week Range:
$4.39
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
4.52 | 363.57M | 129.42M | 17.38M | 13.15M | 0.2043 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Street Watch: Is Niagen Bioscience Inc stock risky to hold nowMarket Activity Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Whale Trades: How do insiders feel about Niagen Bioscience Inc2026 Macro Moves & Breakout Confirmation Alerts - baoquankhu1.vn
Niagen Bioscience doubles share buyback program to $20 million By Investing.com - Investing.com Canada
Niagen Bioscience Increases Share Repurchase Program to $20 Million - PharmiWeb.com
Niagen Bioscience Doubles Share Repurchase Authorization to $20M - TipRanks
Niagen Bioscience doubles share buyback program to $20 million - Investing.com
Niagen Bioscience raises share buyback authorization to $20M, $2.6M repurchased to date - TradingView
Niagen Bioscience (NAGE) boosts share repurchase authorization to $20 million - Stock Titan
Will Niagen Bioscience Inc outperform its industry peers2026 Price Action Summary & Verified Chart Pattern Signals - baoquankhu1.vn
Niagen Bioscience, Inc. announces an Increase in Equity Buyback. - marketscreener.com
Niagen Bioscience to Present at the 38th Annual ROTH Conference - PharmiWeb.com
Niagen Bioscience research program reaches 300 material agreements By Investing.com - Investing.com South Africa
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Nia - PharmiWeb.com
Niagen Bioscience research program reaches 300 material agreements - Investing.com
National Advertising Division Recommends Niagen Update Tru Niagen NAD+ Claims - Happi | Household And Personal Products Industry
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen - Business Wire
Niagen Bioscience reaches 300 research agreements milestone By Investing.com - Investing.com Australia
Latest NAGE NewsNiagen Bioscience Announces Pharmaceutical-... - Stock Titan
Decliners Report: What is the Moat Score of Niagen Bioscience Inc2026 Retail Activity & Safe Entry Momentum Tips - baoquankhu1.vn
National Advertising Division Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Claims; Niagen to Appeal - The Manila Times
Bank Watch: How correlated is Niagen Bioscience Inc to the S P5002026 Intraday Action & Low Drawdown Trading Strategies - baoquankhu1.vn
Analyst Calls: Can Niagen Bioscience Inc stock outperform in a bear marketRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Chart Watch: Is Niagen Bioscience Inc stock risky to hold nowMarket Volume Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Niagen Bioscience (NAGE) Earnings Transcript - AOL.com
Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line - MSN
Niagen Bioscience Launches Niagen Skincare Innovation Lab - Happi | Household And Personal Products Industry
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and D - GuruFocus
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen® - 巴士的報
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen - itemonline.com
Earnings call transcript: Niagen Bioscience’s Q4 2025 revenue grows 16% - Investing.com Nigeria
Risk Off: Is now the right time to enter Niagen Bioscience Inc2026 Momentum & Risk Managed Investment Signals - baoquankhu1.vn
Is Niagen Bioscience Inc. (OCD1) stock undervalued historically2026 Top Gainers & Safe Entry Trade Reports - Naître et grandir
Sentiment Review: Can Niagen Bioscience Inc be recession proofTrade Entry Report & Safe Entry Trade Reports - baoquankhu1.vn
Why Niagen Bioscience Inc. stock appeals to dividend seekersForecast Cut & Low Risk High Reward Ideas - Naître et grandir
Niagen Bioscience (NASDAQ:NAGE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Value Recap: Will Niagen Bioscience Inc stock hit new highs in YEAR - baoquankhu1.vn
Niagen Bioscience (NAGE) Margin Rise To 13.4% Tests Bullish Narrative Targets - simplywall.st
Analysts Are Bullish on These Healthcare Stocks: Niagen Bioscience (NAGE), Daxor (DXR) - The Globe and Mail
Niagen Bioscience rallies 18% after hours: Here's why - MSN
Niagen Bioscience FY25 Net Sales Jump 30%; Sees 10-15% Growth In FY26 - Nasdaq
Canaccord Genuity Group Cuts Niagen Bioscience (NASDAQ:NAGE) Price Target to $13.00 - MarketBeat
Niagen Bioscience 2025 Financials: $129.4M Revenue, $17.4M ProfitNews and Statistics - IndexBox
Niagen Bioscience (NAGE) Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook - simplywall.st
Niagen Bioscience Rallies 18% After Hours: Here's Why - Benzinga
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED) - Benzinga
NAGE Earnings History & Surprises | EPS & Revenue Results | NIAGEN BIOSCIENCE INC (NASDAQ:NAGE) - ChartMill
Niagen Bioscience Inc (NAGE) Q4 2025 Earnings Call Highlights: S - GuruFocus
Niagen Bioscience earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Niagen Bioscience (NAGE) Reports Strong Q4 and Ambitious 2026 Pl - GuruFocus
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income I - PharmiWeb.com
Niagen Bioscience (NAGE) Surges 39% Following Q4 Results and Pos - GuruFocus
Niagen Bioscience Inc Stock (NAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):